申请人:Amgen Inc.
公开号:US20190343838A1
公开(公告)日:2019-11-14
Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.